The use of vascular prostheses to unite or replace injured blood vessels has yielded satisfactory results in many circumstances. However, under conditions of low flow and in reconstructions of small diameter vessels, very poor long-term patency is obtained (1, 2) . In these circumstances only autogenous grafts seem to be suitable since synthetic grafts develop spontaneous thrombosis, or later on, luminal narrowing due to exuberant intimal thickening. The fundamental difference between autogenous grafts and synthetic prostheses is thought to be the presence of an endothelial cell lining (3) . Extensive research efforts have therefore been aimed at the development of antithrombogenic linings in synthetic vascular prostheses by endothelial cell seeding. Several laboratories have shown that in dogs the cumulative patency rates at low rates of flow are enhanced by immediate endothelial cell seeding, but initial human trials with endothelium seeded vascular prostheses have yielded rather conflicting results (3) (4) (5) . The flattened endothelium provides a smooth gliding surface for the circulating blood and for a long time it was thought that this was the only function of the endothelium. However, in the last decades it has become increasingly clear that the endothelium, with its strategic position between tissue and circulating blood, can be regarded as a highly active metabolic and endocrine organ, generating many important substances that mediate numerous and complex interactions between cellular and other elements of the vascular wall and the blood. One of these endothelial substances, which was discovered one decade ago, and which has received increasing interest in vascular research, is the endothelium-derived relaxing factor, EDRF. This paper discusses the potential role of this substance in the prevention of graft failure.
Brlet history of EDRF
The history of EDRF started in the laboratory of Furchgott in 1980 when he observed that acetylcho-line elicited a relaxation of rabbit aortic rings only when the preparations were lined with an intact layer of endothelial cells, while preparations in which the endothelium was removed reacted with a contraction (6) . These initial observations have led to a complete reexamination of the effects of vasoactive substances on different vascular preparations, and from this exploded field of research it has now become clear that the endothelial cells can modulate the vascular effects of a great number of endogenous substances such as acetylcholine, histamine, ADP, ATP, serotonin, bradykinin, aggregating platelets etc ... and this in a wide variety of vessels, including conduit arteries, resistance vessels and also in veins (although less pronounced than in arteries) and from all kinds of species, including man (7, 8) . The initial in vitro observations of endothelium-mediated effects proved to be also relevant for the in vivo vascular responses to vasoactive agents and flow (9, 10) . There exists, however, an important heterogeneity in endotheliumdependent responses not only between species but also between different regions (11, 12) .
The original sandwich techniques (6, 13) , and later, the cascade-transfer (14, 15) experiments, have demonstrated that the greatest part of the modulating influence of the endothelium on the underlying smooth musche cells is to be attributed to a diffusable chemical mediator, for which the name endothelium-derived relaxing factor (EDRF) has been coined. The chemical identity of this EDRF remained elusive for many years, which is not surprising considering the lability of the factor. Half-lives were reported ranging from only 6 seconds to 50 seconds depending on the experimental conditions (16) . On the other hand strong evidence accumulated that EDRF initiates relaxation by stimulating guanylate cyclase, increasing cGMP levels (17, 18) . This mechanism of action was already known to be responsible for the relaxing effects of nitrovasodilator substances such as sodium nitroprusside, amylnitrite, nitroglycerin, isosorbidedinitrate, SIN-1 etc. However, the nitrova-sodilator substances do this without the intervention of the endothelial cells. This similarity in the mechanism of action of EDRF, and the nitrovasodilator substances at the smooth muscle level, has led to convincing evidence that at least one of the EDRF's can be identified as a very simple molecule, namely nitric oxide (NO). NO, in fact, is also the active principle of the nitrovasodilator substances at the cellular level (19) . The physiological precursor of this EDRF (NO) is the amino acid L-arginine, which releases NO in its enzymatic conversion to L-citrulline (20, 21) .
More recently it has become apparent that EDRF not only has relaxant properties but that it also has an inhibiting effect on platelet aggregation (22, 23) . This anti-aggregating effect is more pronounced when EDRF is released together with prostacyclin (which is the case under the influence of many stimuli), as those two substances have a synergistic influence on each other (24) . Besides its anti-aggregatory effect, EDRF has also been shown to inhibit the adhesion of platelets to endothelial cells, an interesting feature that EDRF does not share with prostacyclin, which is only a weak inhibitor of platelet adhesion (25) .
EDRF and vascular grafting
That EDRF, with its vasodilating, anti-aggregating and inhibitory effect on platelet adhesion, may be important for the patency of vascular autografts was suggested by Luscher et al. (26) . They studied endothelium-dependent relaxation in two human vessels which are frequently used to construct coronaryartery bypass grafts, namely the internal mammary artery and the saphenous vein. They found that acetylcholine and other substances elicit endotheliumdependent relaxations in both vessels, but these relaxations were much more pronouced in the internal mammary artery than in the saphenous vein. From this they suggested that the greater patency rate of the arterial grafts compared to venous grafts might be related with the more effective release of EDRF in mammary artery grafts. Indeed, local differences in the ability of the endothelial cells to produce EDRF might be important in selecting blood vessels for vascular grafting. If we assume that grafts behave like normal arteries it can be expected that when blood flow to an organ increases this will elicit a flow-648 induced augmented release of EDRF and dilation of the graft (9) . When platelet aggregation occurs with activation of the coagulation cascade in an arterial graft with intact endothelium, thrombin and platelet products such as serotonin, ADP and ATP will cause an immediate release of EDRF. The resulting dilatation may tend to flush away the beginning thrombus before it endangers the circulation. In addition the EDRF released will inhibit platelet adhesion and aggregation at sites where platelets are activated; this may prevent or limit local thrombus formation. EDRFinduced inhibition of platelet aggregation also results in a reduced release of mitogenic substances (27) such as the platelet derived growth factor (PDGF), which has been implicated as a cause of fibromuscular hyperplasia and might participate in the production of atherosclerotic proliferative lesions which can eventually occlude the lumen of the vessel.
These considerations are only valid if we assume that vascular grafts behave like normal blood vessels. Whether this assumption can indeed be made can only be settled by comparing the reactivity of grafts with the reactivity of normal control vessels. To our knowledge, no such studies were performed on arterial grafts. Miller et al. (28) studied the reactivity of dog femoral veins implanted in the dog femoral arterial system. They reported that the responses to endothelium-dependent substances are decreased in implanted grafts. However, as the response to exogenous nitric oxide was also depressed, the decreased response to EDRF-mediated substances was not attributed to a decreased release of EDRF, but rather to a decreased sensitivity of the smooth muscle cells to EDRF.
Another important observation has been reported by Christie et al. (29) . They investigated the influence of storage and standard surgical preparation of. human saphenous veins on the release of EDRF. They found that storage in either heparinised Hartmann's solution or heparinised whole blood results in diminished EDRF release and that this reduction was more pronounced after a routine surgical preparation consisting of adventitial stripping, sidebranch ligation and distension with saline at pressure below 300 mm of mercury. Such decreased release was also reported for prostacyclin and was attributed to destruction of the endothelium (30) . As regeneration of the endothelial cells will rapidly recover the surface of the graft, one might consider that this decreased reactivity is unimportant (31) . However, it is very striking that regenerated endothelial cells lose the ability to release EDRF in response to certain stimuli. This has been shown by Shimokawa et al. (32) , who denuded pig coronary arteries with a balloon catheter and investigated the segments from the denuded area four weeks later. Histologically they found regrowth of the endothelial cells and normal endothelium-dependent relaxations to several substances. However, the response to aggregating platelets was dramatically changed from a relaxation to a contraction in the zones with regenerated endothelial cells. These zones thus behave almost like endothelium-denuded vessels, with respect to their reactivity to aggregating platelets.
What about the cultured endothelial cells which are used for seeding on vascular grafts? It has been demonstrated that cultured endothelial cells keep the ability to release sufficient amounts of EDRF under appropriate stimulation to relax vascular tissue on which they are seeded (15, 33) . On the other hand it has been shown that some stimuli, i.e. acetylcholine, lose their ability to release EDRF, probably because the specific receptor is lost (33, 34) .
Wilson et al. (35) demonstrated that it was possible to implant vascular grafts lined with genetically modified endothelial cells. This observation opens impor-
